Amendments to the Claims: This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (**Currently Amended**) A sterile aqueous pharmaceutical composition for parenteral administration of propofol, said composition ~~comprising~~ consisting essentially of about 1% (w/v) propofol and less than 15% (w/v) excipients, said excipients ~~comprising~~ consisting essentially of:
7% to 9% (w/v) poloxamer component consisting essentially of Poloxamer 188;
2% to 4% (w/v) polyethylene glycol; ~~and~~
less than 1% (w/v) lipid~~;~~,
0.5 to 2% (w/v) propylene glycol;
an antimicrobial agent; and,
a pH modifier,
wherein the ~~composition further comprises less than 5% (w/v) of total propofol degradants when maintained at 40 °C for 4 weeks, and the~~ composition is clear to the naked eye.

2 - 5. (Canceled)

6. (**Currently Amended**) The composition of Claim 1, wherein said polyethylene glycol ~~comprises~~ is polyethylene glycol 400~~, and wherein said excipients further comprise one or more compounds selected from the group consisting of citric acid, disodium edetate, metabisulfate, benzyl alcohol, propylene glycol, an antioxidant, a preservative, an antimicrobial agent, and a microbicidal~~.

7. (Canceled)

8. (Previously Presented) The composition of Claim 1, wherein:

a) said composition has a particle size diameter of between 25 and 200 nm;

b) said composition has a particle size diameter of between 50 and 100 nm; or

c) said composition forms particles of similar particle size.

9. (Previously Presented) The composition of Claim 1, wherein:

a) said composition does not support microbial growth; or

b) said composition is microbicidal.

10. (Canceled)

11. (**Canceled**)

12. (**Canceled**)

13.-24. (Canceled)

25. (**Currently Amended**) A sterile aqueous pharmaceutical composition for parenteral administration of propofol, said composition ~~comprising~~ consisting essentially of about 1% (w/v) propofol and less than 15% (w/v) excipients, said excipients ~~comprising~~ consisting essentially of:
7% to 9% (w/v) poloxamer component consisting essentially of Poloxamer 188;
2% to 4% (w/v) polyethylene glycol;
0% to 1% (w/v) propylene glycol;
an antimicrobial agent;
a pH modifier;
and less than 1% (w/v) lipid, wherein the composition is clear to the naked eye.

26. (**Currently Amended**) The composition of Claim 25, wherein said excipients ~~comprise:~~ consist essentially of 8% (w/v) Poloxamer 188; 3% (w/v) polyethylene glycol 400; ~~and~~ 1% (w/v) propylene glycol, an antimicrobial agent, and a pH modifier.

27. (Previously Presented) The composition of Claim 1, wherein said composition is stored in a container having a means for dispensing the composition.

28-29. (**Canceled**)